October 2, 2023
Takeda Pharmaceutical said on September 29 that it has filed a new drug application in Japan for fruquintinib, an oral tyrosine kinase inhibitor licensed from Chinese partner Hutchmed, for the treatment of previously treated metastatic colorectal cancer (CRC). The submission...read more